TOP HEADLINES

Featured Story

UPDATED: FDA agrees to review Endo Pharmaceutical's inside-the-cheek pain drug

Endo Pharmaceutical's investigational Belbuca buccal film strip for severe chronic pain has been accepted for review by the FDA, marking a win for the BioErodible MucoAdhesive technology to deliver drugs across mucosal surfaces like the inside of the cheek. And BEMA platform developer BioDelivery Sciences receives a $10 million milestone payment.

MIT team injects drug-carrying hydrogel that 're-heals' in the body

A team of MIT scientists has designed a new injectable hydrogel made from nanoparticles that could someday be used to hold drugs in the body, treating diseases such as cancer, macular degeneration and heart disease.

OncoSec's intratumoral delivery platform to be tested on new partner's cancer candidates

Oncology company Heat Biologics is partnering with OncoSec, developer of the ImmunoPulse intratumoral DNA delivery platform. The two companies will evaluate the combination of the immunotherapy approaches developed by each company, according to the release.

Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel

Prometheon Pharma says it has developed a breakthrough transdermal drug delivery system that can passively deliver large molecules like human growth hormone (which has a size of 2,200 daltons) across the skin.

UPDATED: FDA agrees to review Pfizer's abuse-deterring opioid candidate

Pharma bigwig Pfizer announced that the FDA has agreed to review the New Drug Application of its abuse-deterring extended-release opioid capsules, dubbed ALO-02.

MORE NEWS

From Our Sister Sites

FierceBiotech

Pushing through on a plan to get out of the early-stage anti-infectives R&D space, AstraZeneca is spinning out its Waltham, MA-based company into an independent biotech, a move that will have an impact on the 95 staffers remaining in the swiftly dwindling operation.

FierceBiotech

South San Francisco's Lyric Pharmaceuticals raised $20.4 million in first-round financing to support its work on a hush-hush gastrointestinal drug.